Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Hsu YC
------>authors3_c=None
------>paper_class1=2
------>Impact_Factor=None
------>paper_class3=0
------>paper_class2=0
------>vol=
------>confirm_bywho=None
------>insert_bywho=m001001
------>Jurnal_Rank=None
------>authors4_c=None
------>comm_author=
------>patent_EDate=None
------>authors5_c=None
------>publish_day=None
------>paper_class2Letter=None
------>page2=
------>medlineContent=
------>unit=000
------>insert_date=20040422
------>iam=2
------>update_date=None
------>author=???
------>change_event=1
------>ISSN=None
------>authors_c=None
------>score=74
------>journal_name=ACTA Cardiologica Sinica
------>paper_name=The Causes and Clinical Outcomes in Acute Myocardial infarction Patients without Primary PTCA
------>confirm_date=None
------>tch_id=092002
------>pmid=19642182
------>page1=
------>fullAbstract=OBJECTIVES: Our aim was to evaluate the effects of early abciximab administration in the ambulance on immediate, short, and long term outcomes. BACKGROUND: Early abciximab administration before primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) is recommended in practice guidelines. However, optimal timing of administration remains indistinct. METHODS: Within a fixed protocol for PPCI, December 2006 was the cut-off point for this prospective study. A total of 179 consecutive patients with STEMI were enrolled, 90 patients received abciximab bolus in the hospital (in-hospital group), and 89 patients received abciximab bolus in the ambulance (in-ambulance group). RESULTS: The two groups were comparable for baseline and angiographic characteristics. The in-ambulance group received abciximab within the golden period (median 63 min). The infarct related artery (IRA) patency at onset of the PCI was four times higher in the in-ambulance group compared to in-hospital group (odds ratio = 4.9, 95% CI 2.4-10.1). Enzymatic infarct size was smaller in the in-ambulance group (cumulative 48-h CK release 8011 vs. 11267 U/L, P = 0.004). This was associated with higher left ventricular ejection fraction (LVEF) at 90 days post-PPCI measured by myocardial scintigraphy (59% vs. 54%, P = 0.01), and lower incidence of heart failure through a median of 210 days of clinical follow-up (3% vs.11%, P = 0.04). CONCLUSION: Early abciximab administration in the ambulance significantly improves early reperfusion in STEMI patients treated with PPCI. Moreover this is associated with a smaller infarct size, improved LV function and a lower risk of heart failure on clinical follow-up.
------>tmu_sno=None
------>sno=8728
------>authors2=Cheng JJ
------>authors3=Lee SH
------>authors4=Shyu KG
------>authors5=Lin SC
------>authors6=Hung HF,Liou JY,Kuan P
------>authors6_c=None
------>authors=Hsu YC
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=None
------>publish_area=None
------>updateTitle=In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
------>language=2
------>check_flag=None
------>submit_date=None
------>country=None
------>no=
------>patent_SDate=None
------>update_bywho=None
------>publish_year=1999
------>submit_flag=None
------>publish_month=None
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z